Translating Discovery Into Cure
Total Page:16
File Type:pdf, Size:1020Kb
TRANSLATING DISCOVERY INTO CURE A REPORT FROM PENN’S ABRAMSON CANCER CENTER A MESSAGE FROM the Director of the Abramson Cancer Center Welcome to the latest report of the Abramson Cancer Center of the University of Pennsylvania. This report highlights major accomplishments of the past year including the renewal of the EXCEPTIONAL National Cancer Institute’s Cancer Center Core Support Grant to the University of Pennsylvania with a designation of exceptional, the highest rating possible. This award recognizes the scientific discoveries, multidisciplinary collaboration and commitment to world-class patient care that define our institution. PRECISION I am grateful for the dedication of the 311 cancer center members whose innovative research is changing the face of cancer today, the clinical and administrative staff who support them, the patients who entrust us with their care, the leadership within the university and participating hospitals, and the donors who, in showing their gratitude for our work, challenge us to do more and better, to find tomorrow’s cure today. Our world-renowned innovations attracted the attention of the White House, which launched its cancer ‘moonshot’ initiative at the Abramson Cancer Center on INNOVATION January 15, 2016. This recognition by Vice President Biden results from your contributions. Similarly, the new collaborative Parker Center for Immunotherapeutic Research recognizes the accomplishments and potential of the cancer immunotherapy research featured in this report. As we celebrate these successes, we strive for better — for a day when there doesn’t need to be a IMPLEMENTATION cancer center. Until then, I invite you to learn more about the Abramson Cancer Center and join us in our fight to eradicate cancer. IMPACT Chi V. Dang, MD, PhD Director, Abramson Cancer Center John H. Glick, MD, Abramson Cancer Center Director’s Professor contents National Moonshot Initiative EXCEPTIONAL Parker Institute at Penn Boosts Immunotherapy Research An Exceptional Year Ensuring Quality Care 03 Your Cancer is Unique Targeting Cure Seeing the Light PRECISION Bolstering An Immune Response Rays Take Shape Personalized Medicine Takes on Tobacco 15 INNOVATION Treating the Exceptions Tomorrow’s Therapies Today Tracking an Invisible Enemy Basser Center Steers BRCA Research 37 IMPLEMENTATION Beyond Philadelphia The Local Footprint The Global Footprint 55 IMPACT Power of Philanthropy The Power of a Name The Time is Now Inspiring Hope Gift of Hope 71 ABRAMSON CANCER CENTER // EXCEPTIONAL 01 EXCEPTIONAL ex • cep • tion • al | ik’sepSH( )n( )l | Forming an exception or rare instance. Unusually excellent. Superior. Extraordinary. Read within to learn about the groundbreaking science, latest technology and outstanding medical care that once again earned Penn's Abramson Cancer Center the designation of exceptional by the National Cancer Institute in 2015. 03 NATIONAL CANCER MOONSHOT (l to r): Vice President Joe Biden with Drs. Levine, June and Gutmann INITIATIVE The Abramson Cancer Center (ACC) was proud to host Vice President Joe Biden as the White House kicked off the National Moonshot Initiative against cancer in January 2016. The initiative is designed to accelerate cancer research to ensure that better prevention and treatment strategies reach patients sooner. 0404 Donald M. O'Rourke, MD; Angela M. DeMichele, MD, MSCE; Chi V. Dang, MD,PhD; Stephen Grubbs, MD; Amy Gutmann, PhD; Vice President Joe Biden; Frances S. Collins, MD, PhD; Howard Krein, MD, PhD; Carl H. June, MD; Robert H. Vonderheide, MD, DPhil During his visit, Vice President Biden toured a first-of-its-kind research hub at Penn that will serve as the epicenter I LOOK FORWARD TO of our personalized T-cell therapy program. He also met with ACC and Penn physicians and scientists with expertise in immunotherapy, cancer prevention, surgery, genomics and other areas critical to answering cancer’s most WORKING WITH THIS PANEL challenging questions. AND MANY OTHERS INVOLVED WITH THE MOONSHOT TO Chi V. Dang Appointed to Blue Ribbon Panel The Abramson Cancer Center’s involvement in the Moonshot Initiative will continue through the appointment of MAKE UNPRECEDENTED Director Chi V. Dang, MD, PhD, to the Blue Ribbon Panel charged with steering the effort. The panel includes clinicians, patient advocates, members of the pharmaceutical industry and experts in immunology, cancer prevention, IMPROVEMENTS IN bioinformatics and genomics, among others. PREVENTION, DIAGNOSIS “I’m honored to be joining this diverse group of cancer researchers and physicians, advocates and industry leaders, all of whom represent communities that are essential players working to better prevent and fight the many forms of the AND TREATMENT OF CANCER. disease,” Dr. Dang said. “I look forward to working with this talented panel to inform scientific direction of the Vice President’s Moonshot as we work toward a cure for the millions who are touched by cancer each year.” The panel will act as a working group of the presidentially appointed National Cancer Advisory Board (NCAB), and, as such, will provide scientific guidance to NCAB, which will convey findings to the National Cancer Institute. In addition to Dr. Dang, ACC member Peter Adamson, MD, of the Pediatric Oncology Program, will serve on the panel. — Joe Biden “This Blue Ribbon Panel will ensure that, as the National Institutes of Health allocates new resources through the Vice President of the United States Moonshot, decisions will be grounded in the best science,” Vice President Biden said in a news release. ABRAMSON CANCER CENTER // EXCEPTIONAL 05 PARKER INSTITUTE AT PENN BOOSTS IMMUNOTHERAPY RESEARCH The University of Pennsylvania is honored to join a first-of- its-kind, national research collaboration to fight cancer with immunotherapy. The Parker Institute for Cancer Immunotherapy unites six of the nation’s top medical schools and cancer Robert H. Vonderheide, MD, DPhil (l) and Carl June, MD (r) centers around a shared aim to accelerate new discoveries and examine T lymphocytes growing in the laboratory for new ways to kill cancer cells. treatments in cancer immunotherapy. 06 WE ARE TREMENDOUSLY EXCITED TO JOIN THIS COLLABORATION, “Working together will enable us to make quicker progress as we translate our laboratory findings into clinical trials,” says Carl June, MD, Richard W. Vague WHICH WILL ALLOW US TO Professor in Immunotherapy and Director of the Abramson Cancer Center’s 1,100 PENN CANCER INVESTIGATE PROMISING Center for Cellular Immunotherapies, who has been appointed overall CLINICAL TRIALS IN 2015 director of Penn’s Parker Institute. NEW IMMUNOTHERAPY The $250 million grant to launch the effort is the largest single contribution ever made to the field of immunotherapy. The funding comes from The AVENUES, OUTSIDE OF OUR Parker Foundation, which was founded by Sean Parker in June 2015 with a INSTITUTIONAL SILOS, IN VERY $600 million gift to spur innovations in the life sciences, global public health and civic engagement. UNIQUE WAYS. Penn will use the funding to set up the Parker Institute at Penn, support 80 PENN laboratory studies and clinical trials, recruit talented faculty and develop early IMMUNOTHERAPY career investigators. An initial investment of $10 to 15 million will grow on CLINICAL TRIALS IN 2015 an annual basis via additional project grants, shared resources and central — Carl H. June, MD funding. Robert Vonderheide, MD, DPhil, Hanna Wise Professor in Cancer Richard W. Vague Professor in Immunotherapy; Director, Center for Cellular Immunotherapies Research and ACC Associate Director for Translational Research, and John Wherry, PhD, Professor of Microbiology and Director of Penn’s Institute for Immunology, serve as co-directors of the institute. See page 24 for more about immunotherapy discoveries at Penn. ABRAMSON CANCER CENTER // PROGRESS REPORT 07 AN EXCEPTIONAL YEAR The past year brought many accolades for Penn’s Abramson Cancer Center, at the forefront of which was the renewal of the National Cancer Institute (NCI) Cancer Center Core Support Grant with a rating of exceptional. This is the highest rating that the NCI awards to cancer centers. The Abramson Cancer Center is one of 69 cancer centers in the United States and one of only 45 comprehensive cancer centers. 040804 NCI Designated Comprehensive Cancer Center What is the NCI Cancer Centers Program? THESE FUNDS ENABLE The 1960s brought awareness that cancer is a complex disease that requires US TO CATALYZE NOVEL a major influx of resources to understand, prevent, treat and cure. In 1971, President Nixon captured the attention of the oncology community by INTERDISCIPLINARY TEAM signing the National Cancer Act and establishing a National Cancer Program. Fifteen cancer centers were born, including, in 1973, one at the University APPROACHES TO CANCER of Pennsylvania. PREVENTION AND TREATMENT NCI-funded cancer centers can be basic, clinical or comprehensive. A comprehensive cancer center demonstrates expertise in both laboratory THAT HAVE THE POTENTIAL TO AN EXCEPTIONAL YEAR science and clinical research and brings added depth to the way in which researchers share knowledge to solve pressing questions in cancer biology, ADVANCE CANCER SCIENCE treatment and prevention. This hallmark bench-to-bedside approach requires The past year brought many accolades for Penn’s Abramson Cancer tremendous resources and a cadre of dedicated researchers and clinicians AND CARE BEYOND WHAT working together to uncover cancer’s greatest mysteries. Our ultimate mission Center, at the